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Background:  Evidence-based  interventions  to improve  inﬂuenza  vaccine  coverage  among  pregnant
women  are  needed,  particularly  among  those  who  remain  unvaccinated  late  into  the inﬂuenza  season.
Improving  rates  of  antenatal  tetanus,  diphtheria  and  acellular  pertussis  (Tdap)  vaccination  is  also  needed.
Purpose:  To  test  the effectiveness  of a practice-,  provider-,  and  patient-focused  inﬂuenza  and  Tdap  vaccine
promotion  package  on  improving  antenatal  inﬂuenza  and  Tdap  vaccination  in the  obstetric  setting.
Methods:  A cluster-randomized  trial among  11 obstetric  practices  in  Georgia  was  conducted  in
2012–2013.  Intervention  practices  adopted  the  intervention  package  that  included  identiﬁcation  of  a
vaccine  champion,  provider-to-patient  talking  points,  educational  brochures,  posters,  lapel  buttons,  and
iPads loaded  with a  patient-centered  tutorial.  Participants  were  recruited  from  December  2012–April
2013  and  included  325 unvaccinated  pregnant  women  in Georgia.  Random  effects  regression  models
were  used  to evaluate  primary  and  secondary  outcomes.
Results:  Data  on  antenatal  inﬂuenza  and  Tdap  vaccine  receipt  were  obtained  for 300  (92.3%)  and  291
(89.5%)  women,  respectively.  Although  antenatal  inﬂuenza  and Tdap  vaccination  rates  were  higher  in
the  intervention  group  than  the  control  group,  improvements  were  not  signiﬁcant  (For  inﬂuenza:  risk
difference  (RD)  = 3.6%,  95%  conﬁdence  interval  (CI):  −4.0%,  11.2%;  for  Tdap:  RD  = 1.3%,  95%  CI:  −10.7%,
13.2%).  While  the  majority  of  intervention  package  components  were  positively  associated  with  antenatal
vaccine  receipt,  a provider’s  recommendation  was  the  factor  most  strongly  associated  with actual  receipt,
regardless  of  study  group  or vaccine.
Conclusions:  The  intervention  package  did  not  signiﬁcantly  improve  antenatal  inﬂuenza  or  Tdap  vaccine
coverage.  More  research  is  needed  to determine  what  motivates  women  remaining  unvaccinated  against
inﬂuenza  late into  the  inﬂuenza  season  to get  vaccinated.  Future  research  should  quantify  the extent
to  which  clinical  interventions  can  bolster  a provider’s  recommendation  for vaccination.  This study  is
registered  with  clinicaltrials.gov,  study  ID NCT01761799.©  2015  The  Authors.  Publis
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. Introduction
Inﬂuenza and pertussis are two infectious respiratory diseases
hat pose danger to pregnant women and newborns. Inﬂuenza
an cause more severe illness in pregnant women than in their
on-pregnant counterparts as evidenced by higher rates of hos-
italization and mortality among pregnant women during the
009–2010 H1N1 pandemic [1–6]. Pregnant women are strongly
ncouraged to receive an inﬂuenza vaccine anytime during preg-
ancy [7]. Research has shown that antenatal vaccination not only
educes maternal inﬂuenza risk, but is associated with reduced
isks of preterm birth and small-for-gestational age birth, espe-
ially among babies born during inﬂuenza season [8]. Furthermore,
aternal antibodies produced following vaccination pass through
he umbilical cord and placenta, and infants of vaccinated mothers
ave been shown to be protected against clinical inﬂuenza dur-
ng the ﬁrst six months of life compared to infants of unvaccinated
others [9,10]. Similarly, antenatal vaccination against pertussis
elps protect young infants from the disease which is most severe
n the ﬁrst few months of life prior to the infants’ eligibility for vac-
ination [11,12]. Since 2012, the Centers for Disease Control and
revention (CDC) has recommended antenatal Tdap vaccination
uring every pregnancy [13].
With annual inﬂuenza epidemics and outbreaks of pertussis
ccurring over the last decade, the American College of Obstetri-
ians and Gynecologists (ACOG) has emphasized the importance
f antenatal inﬂuenza and Tdap vaccine receipt [14,15]. Despite
hese endorsements, national antenatal inﬂuenza vaccination cov-
rage estimates hover around 50% and state-based estimates of
dap vaccine receipt during pregnancy have typically not exceeded
0% [16–18].
Substantial research has explored facilitators and barriers
o vaccinating pregnant women, especially against inﬂuenza
19–22]. Barriers can arise from a variety of sources, including a
oman’s personal hesitancy or lack of knowledge about vaccina-
ion during pregnancy. These challenges are partly attributable
o lack of education and/or support of vaccination on the part
f obstetric care providers [23–25]. Less research has focused on
cientiﬁcally evaluating interventions to barriers associated with
aternal vaccination. Many studies have focused on single mes-
age delivery interventions via educational brochures, provider
ecommendations or text-message reminders [26–29]. Few stud-
es have examined the impact of multi-component interventions on
mproving antenatal vaccination rates within the obstetric setting
30]. The purpose of this study is to evaluate the effectiveness of
 comprehensive practice, provider, and patient-focused vaccine
romotion package on improving the likelihood that a pregnant
oman receives an inﬂuenza and/or Tdap vaccine before delivery.
. Methods
.1. Study design and initiation
To evaluate the effectiveness of the intervention package (i.e.
he package; described below), we employed a cluster-randomized
rial design involving randomization of obstetric practices to
wo intervention groups. Unvaccinated pregnant women were
ecruited from each practice and followed to 3 months post-partum
o assess outcomes. Due to late receipt of study funding, patient
ecruitment was initiated later in the 2012/2013 inﬂuenza season
han anticipated..2. Practice recruitment
We  recruited ten obstetric practices from Georgia from August
012 through November 2012 to participate in the Emorye 33 (2015) 3571–3579
MOMVAX study. Practice eligibility criteria included willingness
to be randomized to either study group and having an estimated
inﬂuenza vaccination rate of <60% among pregnant patients dur-
ing the previous 2011/2012 season. If a practice did not offer
inﬂuenza vaccine in the 2011/2012 season, their antenatal vaccina-
tion rate was estimated to be 29% based upon the 2009 state-wide
Georgia antenatal vaccination rate [31]. One interested practice
was deemed ineligible due to having an estimated vaccination rate
exceeding 60%.
Prior to randomization, practices were pair-matched on factors
known to be associated with antenatal inﬂuenza vaccine receipt:
provision of inﬂuenza vaccination in-house, percent patient pop-
ulation on Medicaid, and estimated inﬂuenza vaccine coverage
among pregnant patients during the 2011/2012 inﬂuenza season.
Assignment of condition (intervention vs. control) within each
matched practice pair was  determined by coin-toss by a biostatis-
tician otherwise unafﬁliated with the study. An 11th practice was
added after randomization to supplement enrollment from one
intervention practice. This study was approved by the institutional
review boards of Emory University and the Medical Center of Cen-
tral Georgia.
2.3. Patient recruitment
Following randomization and provision of the package to the
6 intervention practices, women were approached and screened
for eligibility by trained study personnel in the practices’ wait-
ing areas after signing in for their appointments. Eligibility criteria
included: ages 18–50 years, able to read and write English, currently
pregnant, and not having received a 2012/2013 seasonal inﬂuenza
vaccine or a Tdap vaccine during their current pregnancy.
Signed informed consent was  obtained from all eligible
women interested in participating. Following consent, each woman
completed a paper-based baseline questionnaire measuring demo-
graphics and knowledge, attitudes and beliefs about infectious
diseases and vaccination during pregnancy.
Upon enrollment, women received a $10 gift card to their choice
of either Target or Walmart. They were also informed that they
would receive a second $25 gift card to either Target or Walmart
upon completion of a follow-up survey 2–3 months post-partum.
2.4. Intervention package
Practices randomized to the intervention group received all
components of the package [Fig. 1]. Package components are avail-
able for download at www.momvax.org
The iPad-based interactive tutorial was a patient-centered edu-
cational iBook-based app explaining the beneﬁts of antenatal
inﬂuenza and pertussis vaccination. Each intervention practice
received 2 iPads pre-loaded with the tutorial. Practices were
instructed to distribute the iPads to obstetric patients in exami-
nation rooms while waiting to be seen by a physician; this period
within a prenatal visit was  determined during preliminary research
to be the time when women  were least distracted, had time to focus
on the 10-minute tutorial, and staff could feasibly account for the
iPads.
The 1-hour in-house training session was provided by the
Georgia Educating Physicians within their Communities (EPIC)
program on the importance of providing vaccinations, including
inﬂuenza and Tdap, within the obstetric setting [32].
All package materials except for the iPad were based upon
approaches found to be previously beneﬁcial in promoting vac-
cination, and where possible, to obstetric patients speciﬁcally
[29,30,33]. The educational content developed for the patient-
focused components of the package (posters, brochures, lapel
buttons and iPad tutorial) was  written at the 8th-grade level
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Pracce-level component descripons
Vacc ine champion A staﬀ memb er idenﬁed by the pracc e to be the primary resou rce fo r vac cine-related
inform aon for allpracce staﬀ . Thi s indi vidu al could hold any posion (i.e. pracce manager,
nurse, phys ician), bu t needed a posive atude about vacc inaon and be willing to pro mote th e
MOMVAX stud y througho ut it s dura on.
Lapel buons Pr oduce d in two sty les, th ese buons promo ted antenatal vaccinao n. All staﬀ we re encouraged
to pin th ese on the la pels of their jackets or sc rub s.
Posters Pr oduce d in two siz es, th e post er promote d antenatal inﬂu enza and Tdap vaccina on. Prac ce s
were encou raged to hang th em in promin ent plac es ar ound their oﬃce inclu ding waing rooms,
exam roo ms, restr ooms and hallways.
Brochure s Brochure s provid ed educa on on the imp ortance of antenata l vacc inaon , comp osion of
inﬂuenza and Tdap vaccines, safety of the vacc ines, min g of vacc ina on and pro tecon of an
infa nt throu gh vaccinang close co ntacts. Bro chu res also provid ed links to addi ona l online
resources about both maternal and childho od imm unizaons.
Pro vid er-level component descripons
Provider-to-
pae nt ta lkin g
points
Based on con tent publis hed by ACOG an d CDC, talkin g po ints for prom ong ante nata l inﬂuenza
and Tdap vaccinaon were prov ide d on colore d pap er to vaccine champio ns. Enou gh copi es for all
staﬀ wer e provided. Thre e primary tal king poi nts wer e pro duce d for each vac cin e, followe d by
addional safety-related talking poin ts. Th e talking poin ts em phasiz ed protecng the fetus and
new born.
Peer-to-peer
vaccin e promo on
educao n
Provid ed over one lunc h sess ion, the peer-to-peer vacc ine prom oon educaon was provided by
the Geor gia Edu cang Physicians in th eir Comm unies (E PIC) program. Led by a nu rse or
physici an, this 1-hou r sess ion covered the imp ortan ce of ant enatal vac cin aon, ps fo r star ng an
in-house vaccin aon pro gram, and ﬁnancial asp ects of managing vaccin es in the obste tric seng.
Paent-level components
IPad-based
interacve tut ori al
Produce d using th e iBook-pla orm , thi s tutorial includ ed text and au dio/video content covering
the importance of vaccinaon duri ng pregnancy, danger s of inﬂuenz a and per tuss is to infan ts,
safety of ante natal vaccina on, ming of ante nata l vaccina on and an int rod ucing to childhood
vacc inaon. Video s includ ed obst etric physicians ta lking about antenatal vaccinaon as well as
two tesmonials fro m mother s whos e infant s co ntracted inﬂu enza and pertus sis.
Maps to local
pharmacie s/h ealth
depa rtment s that
Provid ed onl y to pracces th at di d not oﬀ er one or both vaccines, these ha ndou ts includ ed a lis t
and map of health departm ents and re tail ou tlet s with in 5 – 10 mil es of a pr acc e. Hando ut also
included facility ad dress es, pho ne num bers , distan ce fr om the pracce, maximum price of
 wheth 
Pracce -level components
-Vaccin e champi on
-Lapel buon s
-Posters
-Brochures
Provider -level compon ents
-Provider-to-paent talking
point s
-Peer -to-peer vac cine
promoon edu caon provi ded
by the Georgia EPIC program
Paent-level compon ents
-iPad -base d interacve
tutorial
-Maps to local
pharmac ies/ hea lth
dep artme nts th at provid e
vaccin es
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Fig. 1. MOMVAX study P3 pac
nd pre-tested among currently or recently pregnant women for
eedback on content, design and usability. The content was also
nformed by our previous work that suggested positive, gain-frame
essaging is preferable than loss-frame messaging in promoting
nﬂuenza vaccination to pregnant women [34].
Control group practices did not receive any package materials
or the duration of the study. They were requested to maintain their
tandard of care regarding inﬂuenza and/or Tdap vaccine promo-
ion and administration.
.5. Outcome measures
The primary outcomes were receipt of inﬂuenza vaccination
nd Tdap vaccination prior to date of delivery. Vaccine receipt
as assessed in 3 ways: obstetric chart review if the vaccine(s)
ere stocked by the patient’s obstetric practice, patient recall
uring a follow-up survey conducted 2–3 months post-partum
nd queries to the Georgia Registry for Immunization Transac-
ions and Services (GRITS) [35]. A priori rules for determining ﬁnaler the facili ty woul d ﬁle insura nce claims.
omponents and descriptions.
antenatal vaccination status are provided in the supplementary
materials.
Secondary outcomes included any Tdap vaccination (antenatal
or post-partum receipt) and recollection of speciﬁc package materi-
als. Recollection of post-partum Tdap vaccination and the package
materials were measured via self-report during the post-partum
follow-up survey. Feedback on the clinical usability of the package
components was collected through post-study interviews with the
vaccine champions at each intervention practice.
2.6. Study power and statistical analysis
We calculated our a priori sample size based upon detecting
a 20% absolute increase in the proportion of women receiving an
antenatal inﬂuenza vaccine among intervention practices com-
pared to control practices with 80% power at the 5% level of
signiﬁcance. A 20% absolute increase was based upon previous
studies obtaining 11–39% increases in vaccination following adop-
tion of single- or dual-component interventions to improve clinical
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Table  1
Characteristics of MOMVAX study practices according to matched pair.
Matched pair 1 Matched pair 2 Matched pair 3 Matched pair 4 Matched pair 5
Intervention Control Intervention† Control Intervention Control Intervention Control Intervention Control
Stocked inﬂuenza
vaccine
Yes No Yes (Yes, but did
not reorder at
initiation of
recruitment)†
Yes Yes, but did not
reorder at
initiation of
recruitment
Yes Yes Yes No No
Stocked Tdap
vaccine
No, but started
on account of
study
No Yes (Yes)† Yes No Yes No Yes No No
Baseline 2011–2012
antenatal
inﬂuenza
vaccination rate
29% 29% 50% (50%)† 50–60% 30% 24% 40% 43% 29% 29%
%  patient population 80% 80% 15% (45%)† 5% 17% 7% 20% 67% 60% 60%
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† Characteristics of the intervention group practice added after randomization ar
accine coverage [27,30,33,36]. Assuming 29% of pregnant women
n Georgia receive an antenatal inﬂuenza vaccination and using an
ntra-cluster correlation coefﬁcient of 0.01, we required a sample
ize of 150 pregnant women per trial group. Assuming 10% loss to
ollow-up at the participant level, our target sample size was 330.
Data are presented as risk differences (RD) and risk ratios (RR)
ith 95% conﬁdence (CIs) intervals unless otherwise noted. SAS
oftware version 9.3 (Cary, NC) was used to analyze the data. Dif-
erences in the likelihood of vaccine receipt between women in
he intervention and control groups were tested in SAS GLIMMIX
sing generalized linear mixed models with a log-binomial link to
alculate relative risks; similar models were ﬁt in SAS NLMIXED
o obtain risk differences and their 95% CIs. A random effect for
ractice was included in models evaluating primary and secondary
utcomes to account for correlation among women recruited from
he same practice. Only variables associated with the outcome
hat appeared imbalanced across study groups after randomiza-
ion were included in covariate-adjusted models. We  used the
ntention-to-treat (ITT) principle to compare outcomes between
he groups, with participants analyzed according to the group to
hich their obstetric practice was randomly assigned. Intraclus-
er correlation coefﬁcients (ICC) were calculated using adjustments
escribed by Yelland et al. for log-binomial models [37].
. Results
Three-hundred and twenty-ﬁve women were enrolled in the
mory MOMVAX study from 11 obstetric practices in Georgia from
ecember 2012–April 2013. Characteristics of the pair-matched
articipating practices are presented in Table 1 and participant
haracteristics stratiﬁed by study group are provided in Table 2.
ost participant characteristics appeared balanced across study
roups, although compared to the control group, mean scores mea-
uring baseline intention to receive either vaccine were slightly
igher in the intervention group (Inﬂuenza: 3.2 vs. 2.6; Tdap: 3.9
s. 3.5) and fewer women were enrolled from practices stocking
he vaccines (Inﬂuenza: 50% vs. 60%; Tdap: 40% vs. 60%).
Data on antenatal inﬂuenza and Tdap vaccine receipt were
btained for 300 (92.3%) and 291 (89.5%) women, respectively
Fig. 2]. Two-hundred seventy-seven (85.2%) women responded to
he post-partum follow-up survey and were included in analyses
f secondary outcomes.
Twenty-seven (9.0%) women received an antenatal inﬂuenza
accine and 32 (11.0%) women received an antenatal Tdap vaccine.
ine (3.0%) received both vaccines prior to delivery. The majority
f women who received either vaccine were white, not Hispanic,
ad health insurance, were enrolled from practices that offered theided in parentheses.
vaccines, and had received a seasonal inﬂuenza vaccine at least one
time in the past ﬁve years. [Data available upon request.] While
intention to receive an antenatal Tdap vaccine as measured at base-
line was of borderline signiﬁcance with regard to actual vaccine
receipt (Mean intention-to receive scores: intervention group: 4.7,
standard error [s.e.]: 3.8 vs. control group: 3.5, s.e. 3.5; p = 0.07),
intention to receive an antenatal inﬂuenza vaccine was signiﬁcantly
associated with receipt (Mean intention-to-receive scores: inter-
vention group: 5.6, s.e. 3.5 vs. control group: 2.5, s.e. 3.0; p < 0.0001).
Women who  received an antenatal Tdap vaccination were also sig-
niﬁcantly more likely to have been enrolled from a practice stocking
Tdap than women  who did not receive a Tdap vaccine during preg-
nancy (78% vs. 51%; p < 0.01)
More intervention group women  received antenatal inﬂuenza
and Tdap vaccines than did control group women, but the absolute
RDs before and after adjustment for the clustered study design were
small and non- signiﬁcant (study-adjusted antenatal inﬂuenza RD:
3.6%, 95% CI: −4.0, 11.2; study-adjusted antenatal Tdap RD: 1.3%,
95% CI: −10.7, 13.2) [Table 3] Although also non-signiﬁcant, women
from the intervention group were nearly 50% more likely to receive
any Tdap vaccine than women  in the control group (RR = 1.47, 95%
CI: 0.70, 3.12), with a 13.1% design-adjusted absolute difference.
Recollection of provider recommendations of antenatal vac-
cination was  strongly associated with antenatal receipt of both
inﬂuenza and Tdap vaccines regardless of study group. Among
intervention group women, no other package component was as
strongly associated with vaccine receipt as the provider’s recom-
mendation [Table 4]. The majority of physical package components
were positively associated with vaccine receipt, with recollection of
the iPad associated with a greater likelihood of antenatal inﬂuenza
vaccination (RR = 3.17, 95% CI: 1.06, 9.53), and recollection of the
lapel buttons resulting in a greater likelihood of any Tdap vaccine
receipt (RR = 1.60, 95% CI: 1.08, 2.37).
3.1. Clinical usability of intervention package components
Regarding the clinical usability of the package, posters were
hung in exam rooms and in ≥1 target area in all 6 intervention prac-
tices. Two  practices indicated receiving inquiries from patients on
account of the posters, and one practice mentioned that the posters
reminded physicians to discuss vaccination.
All intervention practices distributed the provider-to-patient
talking points, primarily during a single staff meeting; however,
vaccine champions would periodically remind physicians and staff
to promote vaccination to pregnant patients. One practice posted
the talking points on a bulletin board in a common break area.
All 5 practice-based vaccine champions believed their staff
learned from the one-hour peer-to-peer vaccine promotion
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Table  2
Participant characteristics by MOMVAX study group.
Characteristic Study group; no. (%) of patients
Intervention (n = 161) Control (n = 164) Total (n = 325)
Maternal age at enrollmenta 26.9 (5.2) 27.5 (6.0) 27.2 (5.6)
Race
Caucasian/White 78 (48) 76 (46) 154 (47)
African American/Black 64 (40) 69 (42) 133 (41)
Asian  2 (1) 5 (3) 7 (2)
Other  or missing 17 (11) 14 (9) 31 (10)
Ethnicity
Hispanic 12 (7) 8 (5) 20 (6)
Non-Hispanic or missing 149 (93) 156 (95) 305 (94)
Parity  (number of current children)a 1.0 (1.1) 1.1 (1.2) 1.1 (1.1)
Education
<High  school graduate/GED 9 (6) 16 (10) 25 (8)
High  school graduate or GED test 69 (43) 58 (36) 127 (39)
Technical/vocational/Associates 32 (20) 41 (25) 73 (23)
Bachelor’s degree or higher 51 (32) 47 (29) 98 (30)
Health insuranceb
Health insurance 19 (12) 25 (15) 44 (14)
Any  private insurance 68 (42) 73 (45) 141 (43)
Medicaid or no insurance 73 (45) 65 (40) 138 (43)
Missing 1 (1) 1 (0) 2 (0)
Number  of times treated by healthcare provider in the past year
0  times 67 (42) 73 (45) 140 (43)
1–4  times 84 (52) 76 (46) 160 (49)
5+  times 7 (4) 13 (8) 20 (6)
Don’t  know 2 (1) 2 (1) 4 (2)
Previous receipt of seasonal inﬂuenza vaccine in past 5 years
0 times 91 (57) 93 (57) 184 (57)
1  time 27 (17) 33 (20) 60 (19)
2–4  times 28 (17) 24 (15) 52 (16)
5  times 6 (4) 5 (3) 11 (3)
Don’t  know 9 (6) 9 (5) 18 (6)
Enrolled from a practice stocking inﬂuenza vaccine 81 (50) 98 (60) 179 (60)
Enrolled from a practice stocking Tdap vaccine 64 (40) 98 (60) 162 (55)
Likelihood of receiving an inﬂuenza vaccine prior to deliverya,c 3.2 (3.4) 2.6 (2.9) 2.9 (3.2)
Likelihood of receiving a Tdap vaccine prior to deliverya,c 3.9 (3.8) 3.5 (3.3) 3.7 (3.5)
a Mean (standard deviation).
b Initial question received by the ﬁrst 50 participants regarding health insurance asked “Do you have health insurance?” Upon noting confusion on behalf of participants,
the  survey was  amended to include 2 questions: “Do you currently have private health insurance?” and “Are you currently covered by Medicaid?”
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raining session provided by Georgia EPIC. One practice not yet
ffering Tdap indicated the training could have been improved
y including more detailed information on the ﬁnancial consid-
rations associated with starting an obstetric Tdap vaccination
rogram.
Most intervention practices found the brochures useful with 3
ntervention practices adding the brochures to new obstetric kits.
ll 6 practices distributed lapel buttons and encouraged wear. For
he 3 practices that received maps of nearby locations to receive
nﬂuenza and/or Tdap because they did not provide the vaccines
n-house, 2 practices physically distributed the lists to patients. The
ther practice preferred to verbally recommend locations to receive
he Tdap vaccine.
Regarding the iPad-based educational app, three practices indi-
ated that managing the iPads (e.g. distributing and collecting them
rom patients, ensuring staff were utilizing them, and conﬁrming
heir security) was challenging. Two practices found the iPads help-
ul for patient education, with one practice indicating the iPad was
elpful in enabling vaccine hesitant patients to articulate questions
o providers. Only one practice indicated the tutorial was hard to
se.ccine to 10 being “Deﬁnitely will” receive the vaccine. Abbreviations: GED, General
4. Discussion
To our knowledge, this is the ﬁrst study to evaluate the effec-
tiveness of a multi-component vaccine promotion package on
improving the likelihood a pregnant woman  receives an inﬂuenza
and/or Tdap vaccine prior to delivery. The absolute differences
in antenatal vaccine uptake were modest and non-signiﬁcant,
yet they favored the intervention group and were comparable in
magnitude to other recent studies evaluating the effectiveness of
single-component interventions to improve antenatal vaccination
[28]. Absolute differences in any Tdap vaccine receipt were larger,
suggesting that addressing Tdap vaccination during pregnancy may
achieve higher, albeit less than ideal, post-partum coverage.
While the results of this study did not ﬁnd a signiﬁcant effect
of the package on antenatal vaccine receipt, it is important to
put this study in context. Late-season participant recruitment may
have dampened the effect of the package since pregnant women
remaining unvaccinated against inﬂuenza by December may  have
been less likely to get immunized than early acceptors. Of the
pregnant women  approached for this study, 59% were ineligi-
ble because they indicated having already received a 2012/2013
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nﬂuenza vaccine and 20% indicated having already received a
dap vaccination [38]. Since remaining unvaccinated late into the
nﬂuenza season is likely correlated with greater vaccine hesitancy,
hese are precisely the types of women among whom evidence-
ased interventions like this package need to be evaluated. While
easonality should not have affected Tdap vaccine uptake, under-
ying vaccine hesitancy could have. Additionally, since we began
nrollment for this study only 2 months after the CDC expanded
he antenatal Tdap recommendations in October 2012 to include
accination at every pregnancy, we anticipated relatively low ante-
atal Tdap vaccine uptake among control group practices [13].
ompared to the antenatal Tdap vaccination rates observed, this
iming could also partially explain the higher rates for any Tdap
accination if obstetric providers – and patients – still relied on
ospitals to vaccinate women who did not receive Tdap during
regnancy.
While the aim of this study was to examine the effective-
ess of the package as a whole, the most noteworthy ﬁnding was
hat a provider’s recommendation remains to be a factor strongly
ssociated with antenatal vaccine acceptance. Despite this, ante-
atal vaccination among those recalling a recommendation was
ow: 16.9% and 25.4% among those recalling a recommendation
or inﬂuenza vaccination and Tdap vaccination, respectively. These
ow percentages may  reﬂect the reticence of this particular pop-
lation of women towards vaccination, suggesting the need for
ore research on effective messaging to women who are not early
cceptors of inﬂuenza vaccination. Moreover, 22% more interven-
ion group women recalled the poster component of the package
han a provider’s recommendation of antenatal Tdap, a ﬁnding
hich signals that researchers designing future intervention stud-
es should intend to measure interactions between the intervention
nd a provider’s recommendation. While this study lacked statisti-
al power to independently examine each package component’st enrollment for MOMVAX study.
interaction with a provider’s recommendation, quantifying the
extent to which future interventions can work synergistically with
a provider’s recommendation will be imperative.
Despite being the most innovative component of the package,
the iPad-based app was  recalled by very few participants, so results
demonstrating a signiﬁcant association between recollection of the
iPad and antenatal inﬂuenza vaccine receipt should be interpreted
cautiously. Providers reported that the devices were cumbersome
to manage and that they were concerned with security of the
devices. In future studies involving electronic tablets for patient
education, collecting more detailed information on device man-
agement, device security, and device usage will be important.
This study has important limitations. It was a small cluster ran-
domized trial, powered to ﬁnd a larger absolute difference between
study groups than what was  observed. Including more practices in
subsequent studies employing a cluster-randomized design would
increase the power to observe smaller, but still clinically relevant
effect sizes. Additionally, we included practices that both stocked
and did not stock vaccine despite the fact stocking vaccine in-house
is a fundamental barrier to vaccine uptake [39–41]. Because the rec-
ommendation to administer Tdap at every pregnancy was so new
at the time of study initiation and excluding practices not offer-
ing vaccines would have limited the diversity of patients included
in our study sample, we  chose to include practices not offering
one or both vaccines and control for this important characteristic
through the pair-matching process prior to randomization. While
ensuring that every obstetric care provider stocks all recommended
vaccines is the ultimate goal, research has shown that concerns
over reimbursement, discomfort with discussions of vaccination
with pregnant patients, vaccine safety and even perceptions of
low disease incidence can inhibit providers’ willingness to stock
vaccine [42]. Despite these barriers, it remains important to test
the effectiveness of interventions to increase antenatal vaccine
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Table 3
Effect of the MOMVAX study intervention package on antenatal inﬂuenza vaccination, antenatal Tdap vaccination, and any Tdap vaccination among women enrolled in the MOMVAX Study.
Antenatal inﬂuenza vaccination (n = 300) Antenatal Tdap vaccination (n = 291) Any Tdap vaccination (n = 291)
Proportions vaccinated in
each study group
Intervention: control: 16/149 (10.7%) 11/151 (7.3%) Intervention: control: 19/140 (13.6%) 13/151 (8.6%) Intervention: control: 61/140 (43.6%) 44/151 (29.1%)
Intervention effect RD (95% CI) RR (95% CI) p-Value ICC RD (95% CI) RR (95% CI) p-Value ICC RD (95% CI) RR (95% CI) p-Value ICC
Unadjusted for study design† 3.5% (−3.0, 9.9) 1.47 (0.71, 3.07) 0.30 N/A 5.0% (−2.3, 12.2) 1.58 (0.81, 3.07) 0.18 N/A 14.4% (3.5, 25.4) 1.50 (1.09, 2.04) 0.01 N/A
Adjusted  for clustered study
design
3.6% (−4.0, 11.2) 1.47 (0.57, 3.81) 0.38 0.01 1.3% (−10.7, 13.2) 1.15‡ (0.22, 6.00) 0.85 0.15 13.1% (−8.9, 35.0) 1.47‡ (0.70, 3.12) 0.27 0.11
Adjusted  for study design and
intention to receive the
vaccine before delivery
0.4% (−2.2, 3.2) 1.12 (0.49, 2.56) 0.77 0.001 1.0% (−8.4, 10.3) 1.13‡ (0.23, 5.71) 0.86 0.13 Model would not
converge
1.47‡ (0.72, 2.99) 0.25 0.10
Adjusted  for study design,
intention to receive the
vaccine before delivery and
stocking vaccine in-house
0.5% (−1.8, 2.8) 1.16 (0.49, 2.78) 0.69 0.001 1.2% (−3.8, 6.1) 1.25‡ (0.26, 6.00) 0.74 0.10 Model would not
converge
1.41‡ (0.65, 3.04) 0.32 0.11
Abbreviations: risk difference (RD); risk ratio (RR); conﬁdence interval (CI); intracluster correlation coefﬁcient (ICC); tetanus; diphtheria and acellular pertussis (Tdap).
† Generated using SAS PROC GENMOD and not accounting for clustered study design.
‡ Random effect for practice is signiﬁcant at p < 0.05 level.
Table 4
Associations between individual intervention package components and vaccine receipt among intervention group women.
Variable measured Unadjusted
proportions
Adjusted for
study design
Unadjusted
proportions
Adjusted for
study design
Unadjusted
proportions
Adjusted for
study design
% Receiving
antenatal
inﬂuenza vaccine
p-Value‡ RR (95% CI) p-Value % Receiving
antenatal Tdap
vaccine
p-Value‡ RR (95% CI) p-Value % Receiving
any perinatal
Tdap vaccine
p-Value‡ RR (95% CI) p-Value
Recollection of OB/GYN or
midwife recommending
antenatal inﬂuenza vaccination
Yes (n = 89) 16.9% <0.01 –+ –+ N/A N/A
No  (n = 48) 0.0%
Recollection of OB/GYN or
midwife recommending
antenatal Tdap vaccination
Yes (n = 63) N/A 25.4% <0.01 0.01 65.1% <0.01 <0.01
No  (n = 73) 2.7% 6.49† (1.55, 27.31) 26.0% 2.45 (1.54, 3.91)
Recollection  of poster about
inﬂuenza and Tdap vaccination
Yes (n = 93) 14.0% 0.14 3.28 (0.77, 17.07) 0.11 10.8% 0.27 0.89† (0.42, 1.88) 0.75 47.3% 0.35 1.26 (0.82, 1.92) 0.29
No  (n = 43) 4.7% 19.1% 38.1%
Recollection  of educational
brochure about inﬂuenza and
Tdap vaccination
Yes (n = 60) 16.7% 0.10 2.57 (0.92, 7.18) 0.07 18.6% 0.13 1.87† (0.86, 4.02) 0.11 47.5% 0.60 1.12† (0.79, 1.60) 0.52
No  (n = 77) 6.5% 9.1% 41.6%
Recollection  of lapel buttons
promoting vaccination worn by
doctors and nurses
Yes (n = 23) 21.7% 0.13 2.49 (0.93, 6.67) 0.07 13.0% 1.00 0.86† (0.31, 2.42) 0.78 65.2% 0.04 1.60 (1.08, 2.37) 0.02
No  (n = 114) 8.8% 13.3% 39.8%
Recollection  of iPad-based
educational app
Yes (n = 10) 30.0% 0.08 3.17 (1.06, 9.53) 0.04 30.0% 0.13 –++ –++ 60.0% 0.34 1.26† (0.76, 2.09) 0.37
No  (n = 127) 9.5% 11.9% 42.9%
Bolded p-values indicate signiﬁcance at p < 0.05 level. Abbreviations: RR, risk ratio; Tdap, tetanus, diphtheria, acellular pertussis; N/A, not applicable.
+ Estimates could not be obtained due to inﬁnite relative risk.
‡ Obtained from Fisher’s exact tests comparing proportions.
† Random effect for practice is signiﬁcant at p < 0.05 level.
++ Random effects model would not converge.
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overage, especially if the interventions are educational in nature
nd can serve to close knowledge gaps related to the importance
f antenatal vaccination for both the providers and patients.
Due to budgetary and practical constraints, not every inter-
ention evidenced to improve vaccine coverage was included in
he package. Notably absent were practice-level interventions like
utomated provider reminders within electronic medical records
EMR) and standing vaccine orders. Not every practice enrolled in
his study used EMRs and since standing orders are only feasible
hen practices stock vaccines, these two evidence-based compo-
ents could not have reasonably been adopted by every practice
n this study. In larger trials with more resources or conducted
nly among practices providing vaccines in-house, inclusion of
hese types of evidenced-based practice-level components would
e worthwhile to include [43].
Key strengths of this study include the multi-facetted nature
f the package, the pair-matched cluster-randomized trial design,
nd the statistical analyses accounting for the clustered design.
ecause barriers to maternal vaccination involve both women
nd their providers, the package was designed to address con-
erns and improve education for both parties. Since each practice
ikely implemented the package materials slightly differently, our
nalysis methods appropriately accounted for practice-based dif-
erences and made a substantial difference in interpretation of
he results from our Tdap models. We  also achieved high rates of
ollow-up, especially for our primary outcomes. Verifying vaccine
eceipt through obstetric chart reviews and GRITS helped mitigate
nformation bias (e.g. recall bias, social desirability bias, vaccine
eporting errors) across both study groups. Any remaining infor-
ation bias is presumed to be non-differential with respect to the
ntervention, thus biasing results towards the null.
With at least 50 studies examining the knowledge, attitudes
nd beliefs of pregnant women towards inﬂuenza vaccination
44], this trial provides necessary research towards development
f evidence-based interventions to improve vaccine coverage. By
eveloping non-burdensome interventions evaluated using study
esigns able to measure the synergy between the intervention and
 provider’s verbal recommendation, we will get closer to obtain-
ng evidence-based interventions effective in pushing antenatal
nﬂuenza and Tdap coverage well beyond 50%.
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